SEC Comment Letter 0000000000-23-002489 to CareMax, Inc. (CMAX, CMAXW) (CIK 0001813914)
CareMax, Inc. (CMAX, CMAXW) (CIK 0001813914)
Date: March 14, 2023 · CIK: 0001813914 · Accession: 0000000000-23-002489
AI Filing Summary & Sentiment
Referenced dates: February 23, 2023, January 17, 2023
Show Raw Text
United States securities and exchange commission logo
March 14, 2023
Kevin Wirges
Chief Financial Officer and Treasurer
CareMax, Inc.
1000 NW 57th Court, Suite 400
Miami, Florida 33126
Re:CareMax, Inc.
Form 10-K for the Year Ended December 31, 2021
Form 10-Q for the Period Ended September 30, 2022
Correspondence Letter dated February 23, 2023
File No. 1-39391
Dear Kevin Wirges:
We have reviewed your February 23, 2023 response to our comment letter and have the
following comments. In some of our comments, we may ask you to provide us with information
so we may better understand your disclosure. Please respond to these comments within ten
business days by providing the requested information or advise us as soon as possible when you
will respond. If you do not believe our comments apply to your facts and circumstances, please
tell us why in your response. After reviewing your response to these comments, we may have
additional comments. Unless we note otherwise, our references to prior comments are to
comments in our January 25, 2023 letter.
Form 8-K Filed March 9, 2023
Exhibit 99.1, page 1
1.We note your response to comment 2. Given that you are continuing to present "de novo
pre-opening costs" and "de novo post-opening costs" amounts, please disclose what each
of these amounts represent and how they are calculated.
2.We note your response to prior comment 3. In regards to your presentation of Platform
Contribution, please explain how you identified operating (loss) income as the
most directly comparable financial measure calculated and presented in accordance with
Generally Accepted Accounting Principles rather than gross profit. Please refer to Item
10(e)(i) of Regulation S-K.
3.Notwithstanding our above comment on the most directly comparable GAAP measure to
Platform Contribution, it is not clear why the cost of care amount presented in your
reconciliation does not agree to the amount presented on your condensed consolidated
FirstName LastNameKevin Wirges
Comapany NameCareMax, Inc.
March 14, 2023 Page 2
FirstName LastName
Kevin Wirges
CareMax, Inc.
March 14, 2023
Page 2
statements of operations. Please clarify. We also note you include a line item called
"other adjustments." As previously requested, please explain the nature and
corresponding amount of each material amount included in any "other adjustments" line
item.
4.In your reconciliation of net income (loss) to Adjusted EBITDA, you include an
adjustment for "Transaction related restructuring costs." Please disclose the nature of
these costs. In your proposed disclosures provided in your letter dated January 17, 2023,
you included an adjustment specifically for DeSpac transaction and related restructuring
costs. If these costs are specific to the DeSpac transaction, please specifically address in
your disclosures why you are continuing to incur these costs in 2022.
5.In your reconciliation to Adjusted EBITDA, the amounts presented for acquisition related
costs for the three months December 31, 2022 and December 31, 2021 as well as the
years ended December 31, 2022 and 2021 do not agree to the amount reflected on your
condensed consolidated statements of operations. Please advise.
Form 10-K for the Year Ended December 31, 2021
Platform Contribution and Adjusted EBITDA , page 44
6.See our comments above regarding your Platform Contribution and Adjusted EBITDA
presentations.
You may contact Nudrat Salik at (202) 551-3692 or Jeanne Baker at (202) 551-3691 if
you have any questions.
Sincerely,
Division of Corporation Finance
Office of Industrial Applications and
Services